云顶新耀(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01952 云顶新耀

香港特别行政区成立纪念日休市 06-30 16:08:07

24.500

-0.160

-0.65%

最高25.160	最低23.720	成交量356.70万
今开24.860	昨收24.660	日振幅5.84%
总市值86.73亿	流通市值86.73亿	总股本3.54亿
成交额8,674万	换手率1.01%	流通股本3.54亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01952","market":"HK","secType":"STK","nameCN":"云顶新耀","latestPrice":24.5,"timestamp":1782806887002,"preClose":24.66,"halted":0,"volume":3567000,"delay":0,"changeRate":-0.006488240064882406,"floatShares":354000000,"shares":354000000,"eps":-1.0278455408892337,"marketStatus":"香港特别行政区成立纪念日休市","change":-0.16,"latestTime":"06-30 16:08:07","open":24.86,"high":25.16,"low":23.72,"amount":86741178,"amplitude":0.058394,"askPrice":24.54,"askSize":1000,"bidPrice":24.5,"bidSize":8000,"shortable":3,"etf":0,"ttmEps":-1.076350611358164,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782955800000},"marketStatusCode":7,"adr":0,"listingDate":1602172800000,"exchange":"SEHK","adjPreClose":24.66,"openAndCloseTimeList":[[1782783000000,1782792000000],[1782795600000,1782806400000]],"volumeRatio":0.7973778942435947,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01952","defaultTab":"news","newsList":[{"id":"2647299558","title":"从资产清单到现金流：云顶新耀重估的真正理由","url":"https://stock-news.laohu8.com/highlight/detail?id=2647299558","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647299558?lang=zh_cn&edition=full","pubTime":"2026-06-30 19:19","pubTimestamp":1782818340,"startTime":"0","endTime":"0","summary":"此前潮药Bar曾讨论过为什么长期看好云顶新耀，但市场对公司的核心质疑一直没有消失：这家公司究竟是一家靠license-in和耐赋康支撑的商业化公司，还是正在形成一套可复制的亚洲Biopharma平台能力？最近一轮密集BD，把这个问题重新摆到了台面上。　　因此，本文的主旨需要更集中：云顶新耀的估值锚，正在从单品rNPV迁移到平台现金流。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-06-30/doc-inifexfn4707566.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-06-30/doc-inifexfn4707566.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1583","159399","BK1574","01952","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647932656","title":"港股异动 | 云顶新耀(01952.HK)涨超7% NMPA已正式受理第三代PCSK9抑制剂乐瑞泊®生物制品上市许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2647932656","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647932656?lang=zh_cn&edition=full","pubTime":"2026-06-29 14:46","pubTimestamp":1782715615,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1583","01952","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647328063","title":"格隆汇2026中期策略峰会“All in 硅基新纪元”暨“金格奖”——卓越公司榜单全部揭晓！","url":"https://stock-news.laohu8.com/highlight/detail?id=2647328063","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647328063?lang=zh_cn&edition=full","pubTime":"2026-06-29 13:08","pubTimestamp":1782709733,"startTime":"0","endTime":"0","summary":"本次评选共设有14个奖项","market":"hk","thumbnail":"https://img3.gelonghui.com/9dec8-575c2ec7-abca-4b10-b7d8-3bd3f2cd0682.jpg?guru_height=741&guru_width=1140&guru_size=148310","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/9dec8-575c2ec7-abca-4b10-b7d8-3bd3f2cd0682.jpg?guru_height=741&guru_width=1140&guru_size=148310"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/5373783","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["02511","03690","000338","00780","02105","02279","300760","01952","00600","02729","00917","06963","09880","09678","01497","02643","02553","01384","02408","002352","01833","01024","09959","01951","02121","002594","000039","09878","02526","002779","06668","002714","001248","000951","02718","01519","02661","300364","002600","01021","06979","09992","02687","02590","03692","02170","02273","02555","01768","07688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152320377","title":"异动解读｜云顶新耀盘中下跌5.48%，耐赋康专利和解引发独家溢价削弱担忧持续发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1152320377","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152320377?lang=zh_cn&edition=full","pubTime":"2026-06-26 11:21","pubTimestamp":1782444104,"startTime":"0","endTime":"0","summary":"6月26日，云顶新耀盘中下跌5.48%，报22.78港元/股，成交额6341.99万港元，延续前一日跌势。耐赋康作为公司核心营收产品，全年销售收入突破14亿元，占公司总收入80%以上。此前公司曾通过广州知识产权法院获得诉前行为保全裁定，如今从对簿公堂转向合作，叠加石药集团布地奈德肠溶胶囊亦已于5月获批，市场对耐赋康独家溢价被削弱的担忧持续升温，股价连续两日承压下行。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153347457","title":"异动解读｜云顶新耀盘中下跌5.15%，耐赋康专利和解允许首仿药上市引发市场担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1153347457","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153347457?lang=zh_cn&edition=full","pubTime":"2026-06-25 10:15","pubTimestamp":1782353753,"startTime":"0","endTime":"0","summary":"6月25日，云顶新耀盘中下跌5.15%，报23.8港元/股，成交额3150.07万港元。消息面上，公司于6月24日宣布与海南合瑞制药就耐赋康相关专利达成谅解，海南合瑞已于去年12月获国家药监局批准的布地奈德肠溶胶囊将获准在中国大陆市场上市，由云顶新耀负责其商业化。耐赋康作为公司核心营收产品，首仿药正式获准入市被市场解读为独家溢价削弱的信号。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645897136","title":"明星肾病药专利大和解！首仿药获准上市，云顶新耀负责商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2645897136","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645897136?lang=zh_cn&edition=full","pubTime":"2026-06-24 19:07","pubTimestamp":1782299220,"startTime":"0","endTime":"0","summary":"两家药企围绕一款明星肾病产品的专利战以和解告终。6月24日，云顶新耀（1952.HK）发布消息称，公司与海南合瑞制药股份有限公司（简称“海南合瑞”）就布地奈德肠溶胶囊（商品名：耐赋康）相关专利达成谅解，并就海南合瑞于2025年12月获得中国国家药品监督管理局批准的布地奈德肠溶胶囊开展商业化合作。海南合瑞的布地奈德肠溶胶囊将获准在中国大陆市场上市，由云顶新耀负责其商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606243781570384.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606243781570384.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IPOS","BK1161","BK1574","01952","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645861935","title":"云顶新耀(01952)与海南合瑞就布地奈德肠溶胶囊达成商业化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2645861935","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645861935?lang=zh_cn&edition=full","pubTime":"2026-06-24 12:34","pubTimestamp":1782275687,"startTime":"0","endTime":"0","summary":"智通财经APP讯，云顶新耀 发布公告，公司与海南合瑞制药股份有限公司就海南和瑞的布地奈德肠溶胶囊达成商业化合作。根据该合作，海南合瑞的布地奈德肠溶胶囊将获准在中国大陆市场上市，并由公司负责其商业化。该合作将有助于提升患者对耐赋康与海南合瑞布地奈德肠溶胶囊的用药选择。2019年6月，公司与Calliditas签订独家授权合约，授权公司在中国内地、香港、澳门、中国台湾和新加坡开发以及商业化耐赋康的权利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457963.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01952","BK1583","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188408955","title":"云顶新耀与海南和瑞医药就布地奈德胶囊达成商业化合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1188408955","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188408955?lang=zh_cn&edition=full","pubTime":"2026-06-24 12:22","pubTimestamp":1782274959,"startTime":"0","endTime":"0","summary":"云顶新耀宣布，已与海南和瑞医药就布地奈德胶囊产品达成商业化合作。此举标志着该公司在特定治疗领域的产品商业化进程迈出了新的一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","01952","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644727225","title":"云顶新耀(01952)获主要股东康桥资本增持71.2万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2644727225","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644727225?lang=zh_cn&edition=full","pubTime":"2026-06-18 07:09","pubTimestamp":1781737762,"startTime":"0","endTime":"0","summary":"智通财经APP讯，云顶新耀(01952)公布，董事会获非执行董事、董事会荣誉主席兼公司主要股东傅唯先生告知，自2026年6月16日至2026年6月17日期间，康桥资本( 作为公司主要股东 )于市场购入71.2万股公司普通股，总代价约为1920万港元，平均价格约为每股股份26.99港元。自2025年12月以来，康桥资本及董事已于市场购入超过516.3万股股份，总代价超过1.725亿港元。董事会认为，购入股份反映公司董事及主要股东对公司未来前景及长远发展的坚定信心。在遵守适用法律及法规的前提下，康桥资本及董事不排除在适当时候进一步增持彼等于公司股份的可能性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455880.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","01952","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178667280","title":"CBC集团于6月16日至17日斥资1920万港元购入71.2万股云顶新耀股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1178667280","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178667280?lang=zh_cn&edition=full","pubTime":"2026-06-18 07:05","pubTimestamp":1781737557,"startTime":"0","endTime":"0","summary":"根据最新披露的权益变动信息，CBC集团在6月16日至17日期间，通过二级市场购入云顶新耀（股票代码：01952）共计71.2万股股份，涉及总金额约为1920万港元。此次增持行动显示出投资机构对该公司前景的关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952","BK1161","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644794095","title":"港股异动 | 云顶新耀(01952)早盘涨超5% 获授抑制剂DMX-200多国开发及商业化权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2644794095","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644794095?lang=zh_cn&edition=full","pubTime":"2026-06-17 10:22","pubTimestamp":1781662955,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，云顶新耀早盘涨超5%，截至发稿，涨4.18%，报27.4港元，成交额4780.47万港元。消息面上，云顶新耀发布公告，宣布与澳洲上市企业Dimerix Limited达成独家授权合作，拿下创新药物DMX-200在大中华区、韩国以及新加坡、马来西亚、泰国等多个东南亚国家的临床开发与商业化权益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455358.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK1161","BK4585","BK4588","DMX","01952","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103772985","title":"云顶新耀达成重磅协议：预付款1000万美元，开发及销售里程碑总额高达3.3亿美元，外加10%-15%销售分成","url":"https://stock-news.laohu8.com/highlight/detail?id=1103772985","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103772985?lang=zh_cn&edition=full","pubTime":"2026-06-16 07:11","pubTimestamp":1781565072,"startTime":"0","endTime":"0","summary":"云顶新耀宣布达成一项具有里程碑意义的授权合作协议。根据协议条款，公司将获得一笔1000万美元的预付款，并有资格获得总额高达3.3亿美元的里程碑付款。这笔款项具体包括：高达3000万美元的开发里程碑款项，以及高达3亿美元的销售里程碑款项。此外，云顶新耀还将根据产品的全球净销售额，获得10%至15%的阶梯式特许权使用费。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","DXB.AU","BK1574","BK7508","01952","BK7501","BK7067","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643412781","title":"云顶新耀(01952)获Dimerix授予独家许可在大中华区、韩国及若干东南亚国家开发及商业化DMX-200","url":"https://stock-news.laohu8.com/highlight/detail?id=2643412781","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643412781?lang=zh_cn&edition=full","pubTime":"2026-06-16 06:58","pubTimestamp":1781564298,"startTime":"0","endTime":"0","summary":"智通财经APP讯，云顶新耀 公布，于2026年6月16日，公司与Dimerix Limited订立协议，据此，Dimerix不可撤销地向公司授予一项独家许可，以在大中华区、韩国及若干东南亚国家开发及商业化DMX-200。DMX-200是一种趋化因子受体2的小分子抑制剂，目前正在进行针对局灶节段性肾小球硬化症的关键性临床3期研究ACTION3。DMX-200已获得美国食品药品监督管理局及欧洲药品管理局的孤儿药资格认定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454717.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1574","DMX","BK1161","01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643822932","title":"【券商聚焦】交银国际：医药行业上半年表现整体稳健 下半年内部分化或加大","url":"https://stock-news.laohu8.com/highlight/detail?id=2643822932","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643822932?lang=zh_cn&edition=full","pubTime":"2026-06-15 10:21","pubTimestamp":1781490116,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，医药行业在1H26表现整体稳健、但内部分化也较为明显。短期关注出海交易、业绩表现和利好政策落地。推荐高景气度赛道中、投资性价比较高的头部玩家，包括药明合联、凯莱英和康龙化成。2026年港股龙头收入和净利润增速有望稳定在双位数。板块复苏积极信号已经出现。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983754","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0051755006.USD","LU0737861772.HKD","LU1242518857.USD","01951","06821","09966","01801","02596","01093","LU1226287875.USD","LU2399975544.HKD","HK0000320264.USD","06160","03692","HK0000306685.HKD","LU0320764599.SGD","LU0140636845.USD","LU0456827905.SGD","01548","02096","06996","BK1191","LU1880383366.USD","LU0502904849.HKD","01177","02162","03329","09926","IE00BZ08YR35.GBP","LU1688375341.USD","LU3063872942.SGD","LU0348827113.USD","01530","09996","06078","06990","LU1960683339.HKD","02268","IE00B0JY6N72.USD","SG9999002562.SGD","LU0819121731.USD","00013","01952","LU2097828631.EUR","01276","02269","LU0181495838.USD","02273","BK1576","03759"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642448900","title":"交银国际：维持云顶新耀(01952)买入评级 海外开发前景可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2642448900","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642448900?lang=zh_cn&edition=full","pubTime":"2026-06-10 13:45","pubTimestamp":1781070322,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，交银国际发布研报称，云顶新耀与多家中国内地药企达成授权许可/资产收购协议，引进多款自免/肾科、心血管、眼科领域重磅单品。该行看好EVER001的海外市场容量和适应症开发前景、以及中国内地商业化产品组合和平台的扩张潜力，维持买入评级。EVER001膜性肾病疗效数据优异，海外开发有望提速公司近期将EVER001的海外权益首予Travere Therapeutics。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452442.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188750965","title":"云顶新耀公告：CBC集团于6月8日至9日斥资1890万港元购入67.9万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1188750965","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188750965?lang=zh_cn&edition=full","pubTime":"2026-06-10 09:45","pubTimestamp":1781055934,"startTime":"0","endTime":"0","summary":"云顶新耀有限公司（股票代码：1952.HK）近日发布公告披露，CBC集团于2026年6月8日至9日期间，在公开市场购入公司股份67.9万股，总交易金额约为1890万港元，每股平均作价为27.9港元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1583","01952","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642941943","title":"【券商聚焦】交银国际维持云顶新耀(01952)买入评级 指BD合作密集落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2642941943","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642941943?lang=zh_cn&edition=full","pubTime":"2026-06-10 09:39","pubTimestamp":1781055568,"startTime":"0","endTime":"0","summary":"倍捷欣已于中国内地获批用于NMOSD，另有膜性肾病处于优先审评阶段。LNZ100 为治疗老视的滴眼液，已在美国获批、并在中国内地递交上市申请，预计1Q27获批。公司近期将EVER001的海外权益首予Travere Therapeutics。该机构看好EVER001的海外市场容量和适应症开发前景、以及中国内地商业化产品组合和平台的扩张潜力，维持买入评级。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983433","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642419555","title":"港股开盘受压 恒指低开0.5% 药明生物(02269)跌4.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2642419555","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642419555?lang=zh_cn&edition=full","pubTime":"2026-06-10 09:26","pubTimestamp":1781054819,"startTime":"0","endTime":"0","summary":"腾讯控股高开0.35%，公司宣布，公司对24.5亿美元及150亿元人民币票据进行定价。当中，10年期和20年期美元票据的本金额，分别为17.5亿美元及7亿美元，利率分别为5%及5.6%，发售价分别占本金额的99.689%及99.571%；10年期和30年期人民币票据的本金额，分别为110亿及40亿元人民币，利率分别为2.5%及3.1%，发售价分别占本金额的100%。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/YjE5MTg4YjVmOWZlYmUxNDMyNzYzODgyMzAy.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjE5MTg4YjVmOWZlYmUxNDMyNzYzODgyMzAy.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983427","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2348773727.SGD","LU0488056044.USD","LU1712237335.SGD","IE00BQXX3F31.USD","BK1184","LU2106854487.HKD","LU0531970944.HKD","LU0593848301.USD","LU0955623706.USD","IE00B0169N27.USD","LU0029875118.USD","LU0348783662.USD","LU0700851271.USD","HK0000288743.USD","LU0080751232.USD","HHImain","LU1102505929.USD","SGXZ23171101.USD","07552","LU0449515922.USD","LU0169518387.USD","IE0003851619.USD","BK1590","SG9999001689.USD","LU0516422366.SGD","LU0188438112.USD","IE00B031HY20.USD","IE0001KFT4U8.USD","LU1974910355.USD","LU0561508036.HKD","BK1521","IE0009570106.USD","LU2237443465.HKD","LU0345769128.USD","SG9999014898.SGD","03067","09088","LU0289961442.SGD","LU2265009873.SGD","LGFRY","BK1191","TCHmain","BK1193","00992","LU1917777945.USD","LU0828237510.HKD","LU0396098781.USD","LU1868837722.USD","LU0499858438.USD","LU2097828805.USD","83115","LU0320764755.SGD","LU1051769294.HKD","LU0370786039.SGD","SG9999002828.SGD","01024","LU0048597586.USD","LU0831093199.SGD","LU0501845795.SGD","LU2294711473.HKD","SG9999017495.SGD","SG9999014005.SGD","LU0261947096.USD","LU0231483743.USD","LU0070217475.USD","LU1226288170.HKD","LU1645745479.HKD","00960","LU1224709979.USD","LU1868837565.USD","LNVGY","LU1130305938.SGD","LU0588545904.SGD","LU0052756011.USD","LU0029874905.USD","LU0192582467.USD","LU0972618739.USD","LU0828237940.HKD","HK0000352291.HKD","IE00BYQQ9H92.USD","SG9999001051.SGD","SG9999014013.SGD","LU1810669033.SGD","LU0648948544.HKD","LU0287142896.SGD","LU1282649067.USD","LU2476274720.SGD","LU1211504680.USD","LU0049112450.USD","BK1576","LU2226246903.HKD","603993","LU0455707207.USD","AAGIY","LU1242518931.SGD","WXXWY","LU0326950275.SGD","LU1688375341.USD","LU2237443622.USD","BK1119","LU2251237488.HKD","IE00B5TLWC47.USD","LU1282648689.USD","IE0008368411.USD","BK1601","LU0633140727.USD","LU2028103732.USD","LU0211977185.USD","LU2089283258.USD","LU1439102457.SGD","HK0000306701.USD","IE00B0169L03.USD","LU1993786604.SGD","LU0117844026.USD","LU1861214812.USD","LU0203345920.USD","LU0269904917.USD","07226","LU1814569148.SGD","00175","LU0650527681.SGD","BK1609","LU2039709279.SGD","LU1883866441.USD","IE00BZ08YR35.GBP","SGXZ81514606.USD","LU0828238088.HKD","SG9999004311.SGD","LU0048388663.USD","LU1008478684.HKD","LU0011963245.USD","LU0203347892.USD","LU0871576103.HKD","IE00BKZH1Z71.USD","LU0971096721.USD","LU0589944569.HKD","SG9999013353.USD","LU0049853897.USD","LU1720050803.USD","HSBA.UK","LU1734074674.USD","03993","IE00B97KM107.HKD","LU1046422090.SGD","LU2097828631.EUR","IE00B0JY6N72.USD","LU0511384066.AUD","BK1610","LU0196878994.USD","LU1316542783.SGD","LU1303224171.USD","SG9999018865.SGD","LU1515016050.SGD","HK0000914686.HKD","LU0320764599.SGD","LU0061477393.USD","LU0164872284.USD","00700","LU2133065610.SGD","LU2462611646.USD","LU0149721374.USD","BK1618","LU0345769631.USD","03423","LU0531971595.HKD","LU0359201885.HKD","LU1769817096.USD","LU0823038988.USD","LU0608807433.USD","LU0106959298.USD","07300","LU0791590937.USD","LU1956131251.USD","SG9999015986.USD","LU1623119135.USD","LU2237443382.USD","LU2111349929.HKD","LU0868486357.SGD","LU1366334578.USD","LU0307460666.USD","LU1202635105.USD","LU1794554557.SGD","SGXZ90724238.SGD","LU1119993845.HKD","LU1981816686.USD","LU0955669360.SGD","LU1785774172.SGD","BK1539","LU2237443895.HKD","LU0326948709.USD","81024","BK1615","IE0008369823.USD","LU0456846285.SGD","IE0032431581.USD","LU0054237671.USD","BK1608","LU0054450605.USD","LU0205439572.USD","BK1516","BK1517","SG9999001226.SGD","LU2177674079.SGD","LU0784639295.USD","IE0004091025.USD","LU1808992512.USD","LU0516422440.USD","LU0823397285.USD","IE00B5MMRT66.SGD","LU1880383366.USD","LU0214875030.USD","LU1044875133.USD","LU1675838814.USD","HK0000320223.HKD","BK1591","LU1267930227.SGD","LU0634319403.HKD","LU1769817179.HKD","LU0738912210.USD","01299","IE00BPRC5H50.USD","IE0034224299.USD","LU1105468828.SGD","LU0348827113.USD","LU0499858602.USD","LU0320764243.SGD","LU0762540952.USD","LU0856984785.SGD","SG9999015978.USD","LU0572940350.SGD","LU0264606111.USD","LU1044876610.USD","LU0158827781.USD","LU0043850808.USD","LU1048484197.HKD","03419","LU2051468812.USD","LU1861219969.SGD","LU0158827948.USD","LU0651947912.USD","LU1242518857.USD","IE00B3T34201.USD","LU1226287529.USD","LU0210527791.USD","02837","LU2778985437.USD","SG9999001846.SGD","03692","SG9999000418.SGD","LU0096374516.USD","SG9999004220.SGD","LU0985320562.USD","LU0314109678.HKD","LU2279701549.SGD","BK1544","LU0611395673.USD","LU0572944931.SGD","LU0577902371.SGD","HK0000288784.HKD","LU0228659784.USD","MCHmain","LU1770036033.HKD","LU2152927971.USD","LU0345776255.USD","LU0456842615.SGD","LU2097828557.USD","IE00B8HQ1Z84.USD","LU0516423091.SGD","LU0918141705.HKD","LU2125910849.SGD","LU0831103253.SGD","IE00BF5LJ272.USD","LU0261950470.USD","LU0165289439.USD","LU1196710864.SGD","LU0878005551.USD","BK1592","LU0128522157.USD","LU0175139822.USD","LU1328615791.USD","SG9999007991.SGD","03033","LU2089284900.SGD","02800","LU0672654166.SGD","LU0557290698.USD","LU0762541174.USD","LU0197773160.USD","LU0057025933.USD","BK1190","LU2247934214.USD","LU0463099449.HKD","LU0244354667.USD","LU0348766576.USD","LU0348816934.USD","LU1831875114.USD","LU2023250504.SGD","IE00B29SXG58.USD","00005","LU0254981946.USD","LU0472753341.HKD","LU1691799644.USD","LU2023251221.USD","HK0001040168.HKD","HSI","LU0345775950.USD","LU2317271919.USD","LU2237443978.SGD","IE00BGV7N243.SGD","LU1226287875.USD","LU2125910500.SGD","LU2271345857.HKD","LU2498475776.HKD","LU0143863784.USD","BK1141","LU0642271901.SGD","LU0348767384.USD","LU0417516902.SGD","LU1733274473.HKD","SG9999001903.USD","LU0791591158.USD","LU1115378108.SGD","LU0084288322.USD","BK1572","LU0251144936.SGD","LU0067412154.USD","BK1589","LU1725190679.HKD","LU0107464264.USD","LU0164865239.USD","BK1588","LU0210533765.USD","80175","LU0235996351.USD","IE00BZ08YS42.EUR","LU0823397103.USD","LU1868838027.USD","SG9999003461.SGD","LU2360107325.USD","LU1282651121.HKD","BK1574","LU0608807946.USD","LU0862451837.USD","LU1400636657.SGD","GB00BDT5M118.USD","IE00B031J352.USD","SG9999015945.SGD","LU0786609619.USD","09999","HK0000306685.HKD","IE0004086264.USD","LU0577902454.USD","LU0708995153.HKD","IE00B031HW06.USD","LU0128525689.USD","LU2097828714.EUR","BK1240","LU0441854154.USD","LU1282649141.HKD","LU0293314216.USD","LU1188198961.HKD","LU1282651048.USD","LU0348735423.USD","LU0163747925.USD","09067","01952","LU0577902538.SGD","07200","LU2476274308.USD","IE0031814852.USD","HK0000352382.USD","LU0456827905.SGD","LU0543330483.HKD","LU0640798160.USD","LU0819123356.HKD","LU1323998911.USD","LU0266013472.USD","LU0259732245.USD","IE0003795394.USD","LU1655091459.SGD","LU0877626530.USD","LU2449936058.SGD","SGXZ51526630.SGD","LU0588546209.SGD","BK1161","LU0651946864.USD","02269","LU0516422952.EUR","LU2399975544.HKD","BK1594","LU0683595622.HKD","LU0384037296.USD","GELYY","KSTmain","LU0449509016.USD","LU0594300419.USD","LU0605514214.HKD","LU1807302812.USD","LU1152091168.USD","LU0132412106.USD","LU0469268626.HKD","LU1642822792.SGD","IE0003895053.USD","LU0359201612.USD","81299","IE0008368742.USD","LU1064130708.USD","SG9999002562.SGD","LU0348784397.USD","SG9999001093.SGD","LU0228367735.SGD","LU1226287792.SGD","LU0181495838.USD","LU0348814723.USD","SG9999014021.USD","LU0329678170.USD","LU1400636574.HKD","SG9999018857.SGD","LU1568876251.USD","LU0106259558.USD","LU0675040207.SGD","LU0072462343.USD","LU2362541273.HKD","HK0001040143.USD","LU1282649810.SGD","SG9999015952.SGD","LU0329678337.USD","LU0823040885.USD","LU2148510915.USD","IE00BZ08YT58.USD","LU2351347302.SGD","LU0197773673.USD","LU0173614495.USD","LU0630378429.USD","IE00B067MR52.USD","02833","LU1363072403.SGD","LU0348783233.USD","LU0047713382.USD","LU0502904849.HKD","LU0149534421.HKD","LU0315178854.USD","LU0862451753.SGD","LU1328277881.USD","LU0873338254.USD","BK1555","LU2008162690.USD","LU0588545490.SGD","SG9999006514.SGD","SG9999002463.SGD","LU2237443549.SGD","LU1629966141.USD","LU1235295612.USD","HSBC","513600","LU0543330566.HKD","06181","SG9999006597.SGD","LU0588545730.USD","LU1951186391.HKD","LU0211331839.USD","LU0823413660.USD","LU0865486749.SGD","LU1568876335.HKD","LU0051755006.USD","LU0229945570.USD","BK1586","LU0918141887.USD","LU0821914370.USD","LU1226288253.USD","LU0310800965.SGD","LU0048575426.USD","LU0880133367.SGD","LU0979878070.USD","TCEHY","LU2362540622.SGD","LU1048596156.SGD","LU1051768304.USD","HTCD.SI","LU0577902298.EUR","LU0823413587.USD","LU0414403682.SGD","80992","LU1733274390.USD","82800","LU0117841782.USD","LU2153592121.USD","LU2293587155.HKD","LU0540923850.HKD","BK1531","IE00B543WZ88.USD","LU1196710351.USD","LU0737861772.HKD","LU1481012133.USD","LU2257852520.SGD","LU0048580855.USD","IE00BQXX3C00.GBP","LU0633140560.USD","LU0509642566.USD","LU0819121731.USD","LU1504937902.USD","LU0164880469.USD","LU0359202008.SGD","LU0882747503.HKD","LU0069063385.USD","03032","SG9999014906.USD","LU1804176565.USD","LU0955648018.USD","HSTECH","LU0128522744.USD","LU0417516571.SGD","LU0823426308.USD","LU0127658192.USD","HK0000914660.USD","LU0289739343.SGD","LU1048588211.SGD","LU0052750758.USD","LU0708995583.HKD","LU2045819591.USD","LU1821325948.USD","LU0143863198.USD","NTES","SG9999014674.SGD","LU0516423174.USD","LU1960683339.HKD","LU1023057109.AUD","LU0072913022.USD","LU0577902611.USD","LU1226288097.SGD","03115","LU2187417386.USD","LU0607220059.USD","LU0039217434.USD","LU1961090484.USD","IE00BQXX3D17.EUR","LU1196710195.USD","SG9999004303.SGD","03143","BK1095","LU2348774022.SGD","LU0417516738.SGD","03037","HSHD.SI","HK0000151867.HKD","LU0348805143.USD","LU0572939691.SGD","SG9999014039.USD","BK1104","LU0140636845.USD","LU1813983027.USD","BK1502","LU2213484517.USD","SGXZ99366536.SGD","LU0541502299.USD","09115","LU0823426480.USD","BK1526","LU0210526637.USD","BK1583","LU2242644610.SGD","LU0797268264.HKD","LU0823039010.USD","LU2251237306.USD","LU0261950983.USD","LU1224444064.USD","EVS.SI","SGXZ31699556.SGD","BK1575","LU2153591404.USD","LU0431992006.USD","LU3063872942.SGD","IE00B3M56506.USD","LU1670756490.USD","LU0898667661.SGD","LU0289960550.SGD","LU0823041008.USD","LU0348825331.USD","LU0594300179.USD","LU0327786744.USD","SG9999014914.USD","LU0251143458.SGD","LU1439103000.SGD","03088","LU0890818403.SGD","LU1481107354.HKD","LU0541501648.USD","IE00BFXG0V08.USD","LU0762542818.HKD","LU2087589342.USD","LU1366334651.USD","SG9999000459.SGD","LU1400636491.USD","LU1152091754.HKD","LU1983260115.SGD","BK1231","LU0886674414.USD","LU0630378692.HKD","LU1044874839.SGD","SG9999014880.SGD","LU1719994722.HKD","BK1607","SG9999000327.SGD","LU0328353924.USD","03417","LU0737861699.HKD","LU2362541513.USD","BK1227","LU0315179316.USD","LU1770034418.SGD","LU2097828474.EUR","LU0348788117.USD","07500","LU1064131003.USD","IE0032834883.USD","LU1880383440.USD","SG9999001069.SGD","LU1251922891.USD","LU0878004406.USD","HK0000320264.USD","IE00B8L5B284.USD","LU0106252389.USD","LU1718418525.SGD","LU1102505762.USD","LU2929501877.USD","LU0348723411.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642416083","title":"中金：维持云顶新耀(01952)跑赢行业评级 目标价41.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2642416083","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642416083?lang=zh_cn&edition=full","pubTime":"2026-06-10 09:12","pubTimestamp":1781053978,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持云顶新耀2026年和2027年盈利预测不变。基于DCF，予跑赢行业评级与目标价41.5港元，较当前股价有48.43%上行空间。该行认为该合作将加速EVER001的全球临床开发和商业化进程，特别是在膜性肾病的开发进程。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452343.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642413615","title":"云顶新耀(01952)获主要股东傅唯增持67.9万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642413615","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642413615?lang=zh_cn&edition=full","pubTime":"2026-06-10 07:10","pubTimestamp":1781046622,"startTime":"0","endTime":"0","summary":"智通财经APP讯，云顶新耀(01952)发布公告，公司董事会获非执行董事、董事会荣誉主席兼本公司主要股东傅唯先生(傅先生)告知，自2026年6月8日至2026年6月9日期间，康桥资本(作为本公司主要股东)于市场购入67.9万股本公司普通股(股份)，总代价约为1890万港元，平均价格约为每股股份27.90港元。据傅先生及康桥资本表示，其透过场内收购方式购入股份，乃基于其对本公司未来前景及长远发展的坚定信心。在遵守适用法律及法规的前提下，傅先生及康桥资本不排除在适当时候进一步增持其于本公司股份的可能性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452305.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1161","BK1574","01952"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.everestmedicines.com","stockEarnings":[{"period":"1week","weight":-0.0301},{"period":"1month","weight":-0.1871},{"period":"3month","weight":-0.3966},{"period":"6month","weight":-0.3375},{"period":"1year","weight":-0.6061},{"period":"ytd","weight":-0.3375}],"compareEarnings":[{"period":"1week","weight":-0.0195},{"period":"1month","weight":-0.0914},{"period":"3month","weight":-0.0954},{"period":"6month","weight":-0.1073},{"period":"1year","weight":-0.0495},{"period":"ytd","weight":-0.1073}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"云顶新耀有限公司是一家主要从事创新药及疫苗研发、临床开发、制造及商业化的生物制药公司。该公司已建立跨肾病、抗感染及自身免疫性疾病的产品管线。该公司的产品管线包括用于肾病治疗领域的耐赋康（TARPEYO）、用于治疗包括临床常见的革兰氏阴性菌、革兰氏阳性菌、厌氧菌等多重耐药菌的感染的依嘉（依拉环素）等产品。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.01035},{"month":2,"riseRate":0.333333,"avgChangeRate":0.039331},{"month":3,"riseRate":0.333333,"avgChangeRate":0.002002},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.092533},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.045773},{"month":6,"riseRate":0.666667,"avgChangeRate":0.224714},{"month":7,"riseRate":0.2,"avgChangeRate":-0.114966},{"month":8,"riseRate":0.2,"avgChangeRate":-0.112869},{"month":9,"riseRate":0.6,"avgChangeRate":0.046163},{"month":10,"riseRate":0.4,"avgChangeRate":-0.024036},{"month":11,"riseRate":0.5,"avgChangeRate":0.086142},{"month":12,"riseRate":0.666667,"avgChangeRate":0.131823}],"exchange":"SEHK","name":"云顶新耀","nameEN":"EVEREST MED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"云顶新耀(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供云顶新耀(01952)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"云顶新耀,01952,云顶新耀股票,云顶新耀股票老虎,云顶新耀股票老虎国际,云顶新耀行情,云顶新耀股票行情,云顶新耀股价,云顶新耀股市,云顶新耀股票价格,云顶新耀股票交易,云顶新耀股票购买,云顶新耀股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"云顶新耀(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供云顶新耀(01952)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}